Twum-Danso NA, 2003-10: Retrospective analysis of the passive surveillance system for serious adverse events in onchocerciasis mass treatment, identifying 65 probable or possible Loa loa encephalopathy cases. Of those with known outcome, 23.5% died and 11.8% were left with a partial neurological deficit.
Clinical outcome was reported in 34 cases: 64.7% recovered fully, 11.8% had partial neurologic deficit and 23.5% died.
Twum-Danso NA, 2003-10: Retrospective analysis of the passive surveillance system for serious adverse events in onchocerciasis mass treatment, identifying 65 probable or possible Loa loa encephalopathy cases. Of those with known outcome, 23.5% died and 11.8% were left with a partial neurological deficit. C4 pharmacovigilance of mass treatment. Study type: retrospective analysis of a sponsor-run passive SAE surveillance system; N=207 serious adverse events, of which 65 PLERM cases; multi-country (97% from southern Cameroon). Dose: Mectizan (ivermectin, Merck Sharp & Dohme) at standard mass-treatment dose. Comparator: none. Funder: the surveillance system is the manufacturer's (Merck/MSD) required programme; no separate funding or conflict statement in the PubMed record. Mean time to onset 1.7 days; 53 hospitalised, mean 27.5 days. Study type: uncontrolled series.
